Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Department of Haematology
54 publications found
The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII
Cell Biosci, 9, 69
DOI 10.1186/s13578-019-0333-8, PubMed 31467667
Surgical procedures in patients with severe haemophilia 1997–2014
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.18.0592, PubMed 31062561
Surgical intervention in patients with severe bleeding disorder 1997-2014
Tidsskr. Nor. Laegeforen., 139 (8), 709-712
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560
Child development, growth and microbiota: follow-up of a randomized education trial in Uganda
J Glob Health, 9 (1), 010431
DOI 10.7189/jogh-09-010431, PubMed 31131103
Nutrition, Hygiene and Stimulation Education for Impoverished Mothers in Rural Uganda: Effect on Maternal Depression Symptoms and Their Associations to Child Development Outcomes
Nutrients, 11 (7)
DOI 10.3390/nu11071561, PubMed 31373314
Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
Hemasphere, 3 (6), e321
DOI 10.1097/HS9.0000000000000321, PubMed 31976490
Venous thromboembolism in the critically ill: A prospective observational study of occurrence, risk factors and outcome
Acta Anaesthesiol Scand, 63 (5), 630-638
DOI 10.1111/aas.13316, PubMed 30623406
Cold agglutinin disease: current challenges and future prospects
J Blood Med, 10, 93-103
DOI 10.2147/JBM.S177621, PubMed 31114413
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group
Eur J Haematol, 102 (3), 235-240
DOI 10.1111/ejh.13198, PubMed 30472746
Enhanced nutrient supply and intestinal microbiota development in very low birth weight infants
Pediatr Res, 86 (3), 323-332
DOI 10.1038/s41390-019-0412-x, PubMed 31086354
Home treatment for pulmonary embolism
Tidsskr Nor Laegeforen, 139 (18)
DOI 10.4045/tidsskr.19.0115, PubMed 31823570
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
J Immunol, 202 (5), 1397-1405
DOI 10.4049/jimmunol.1701703, PubMed 30692213
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A
Res Pract Thromb Haemost, 3 (3), 542-554
DOI 10.1002/rth2.12220, PubMed 31294338
Immune Thrombocytopenia
N Engl J Med, 381 (10), 945-955
DOI 10.1056/NEJMcp1810479, PubMed 31483965
A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.
Leuk Lymphoma, 60 (10), 2404-2414
DOI 10.1080/10428194.2019.1594215, PubMed 30997844
Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
Haemophilia, 25 (3), 373-381
DOI 10.1111/hae.13712, PubMed 30817066
Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis
Thromb Haemost, 119 (9), 1481-1488
DOI 10.1055/s-0039-1692426, PubMed 31254974
Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment
Blood Coagul Fibrinolysis, 30 (1), 17-23
DOI 10.1097/MBC.0000000000000784, PubMed 30507711
Pre-formulation investigations for establishing a protocol for treosulfan handling and activation
Pharm Dev Technol, 24 (5), 639-648
DOI 10.1080/10837450.2018.1551903, PubMed 30474459
Does the Villalta scale capture the essence of postthrombotic syndrome? A qualitative study of patient experience and expert opinion
J Thromb Haemost, 17 (10), 1707-1714
DOI 10.1111/jth.14557, PubMed 31265193
Limitations of the Villalta scale in diagnosing post-thrombotic syndrome
Thromb Res, 184, 62-66
DOI 10.1016/j.thromres.2019.10.018, PubMed 31707153
STIM1 R304W in mice causes subgingival hair growth and an increased fraction of trabecular bone
Cell Calcium, 85, 102110
DOI 10.1016/j.ceca.2019.102110, PubMed 31785581
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists
Platelets, 31 (3), 322-328
DOI 10.1080/09537104.2019.1639655, PubMed 31280643
Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists
Platelets, 31 (2), 198-205
DOI 10.1080/09537104.2019.1585527, PubMed 30885035
Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists
Thromb Res, 185, 119-124
DOI 10.1016/j.thromres.2019.11.031, PubMed 31805421
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT
Leukemia, 34 (1), 87-99
DOI 10.1038/s41375-019-0527-4, PubMed 31363160
Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials: A Systematic Review and Meta-Analysis
Stroke, 50 (8), 2187-2196
Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women
Thromb Res, 184, 1-7
DOI 10.1016/j.thromres.2019.10.005, PubMed 31677448
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Haematologica, 105 (6), 1723-1730
DOI 10.3324/haematol.2019.222810, PubMed 31439677
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Lancet Oncol, 20 (6), e302-e312
DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104
Inheritance of Susceptibility to Malignant Blood Disorders
Sci Rep, 9 (1), 2444
DOI 10.1038/s41598-019-38879-y, PubMed 30792429
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Haemophilia, 25 (6), 1011-1019
DOI 10.1111/hae.13853, PubMed 31621991
Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway
Cancer Epidemiol, 60, 128-133
DOI 10.1016/j.canep.2019.04.002, PubMed 30986631
Abnormal blood lactate accumulation during repeated exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome
Physiol Rep, 7 (11), e14138
DOI 10.14814/phy2.14138, PubMed 31161646
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study
Haemophilia, 25 (2), 334-342
DOI 10.1111/hae.13640, PubMed 30715788
The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress
J Biol Chem, 294 (20), 8197-8217
DOI 10.1074/jbc.RA118.002829, PubMed 30926605
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e459-e469
DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687
Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP)
Sci Rep, 9 (1), 18990
DOI 10.1038/s41598-019-55531-x, PubMed 31831842
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Biol Blood Marrow Transplant, 26 (4), 659-664
DOI 10.1016/j.bbmt.2019.11.021, PubMed 31759159
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol, 20 (6), 781-794
DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405
Housing, water and sanitation implications on food insecurity and diet diversity in landslide affected communities: A cross-sectional survey of two districts in Uganda
Clin Nutr ESPEN, 33, 47-56
DOI 10.1016/j.clnesp.2019.07.010, PubMed 31451275
Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma
Thromb Res, 182, 124-132
DOI 10.1016/j.thromres.2019.08.016, PubMed 31479940
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Biol Blood Marrow Transplant, 25 (9), 1875-1883
DOI 10.1016/j.bbmt.2019.05.007, PubMed 31085303
Altered oxidative stress and antioxidant defence in skeletal muscle during the first year following spinal cord injury
Physiol Rep, 7 (16), e14218
DOI 10.14814/phy2.14218, PubMed 31456346
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Cancers (Basel), 11 (8)
DOI 10.3390/cancers11081088, PubMed 31370273
Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients
Bone Marrow Transplant, 54 (12), 2102-2109
DOI 10.1038/s41409-019-0638-6, PubMed 31455897
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
Leukemia, 34 (2), 478-487
DOI 10.3324/haematol.2018.192328, PubMed 31471562
Transcription factor FOXP3: A repressor of the TFPI gene?
J Cell Biochem, 120 (8), 12924-12936
DOI 10.1002/jcb.28563, PubMed 30861202
Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells
Aging Cell, 18 (2), e12897
DOI 10.1111/acel.12897, PubMed 30712319
Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood
J Immunol, 203 (6), 1571-1578
DOI 10.4049/jimmunol.1900047, PubMed 31413105
Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality
Cancer Genomics Proteomics, 16 (3), 175-178
DOI 10.21873/cgp.20123, PubMed 31018948
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e448-e458
DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)
Bone Marrow Transplant, 54 (9), 1391-1398
DOI 10.1038/s41409-019-0448-x, PubMed 30664723